Impact of Fever Prevention in Brain Injured Patients (INTREPID)
This study will assess the impact of fever prevention on fever burden and short- and long-term neurologic outcomes in brain injured patients. Half of the subjects will undergo fever prevention using a targeted temperature management system and half of the subjects will be treated for fever should it develop.
-Admitted with a primary neurological diagnosis of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage.
-Prior to onset of acute symptoms, was considered functionally independent (mRS 0-2).
-Meets disease-specific criteria for ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage.
-Fever (≥38°C) prior to study enrollment.
-Has a skin condition in which the use of the ArcticGel Pads is contraindicated (i.e., skin that has signs of ulceration, burns, hives, or rash).
**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at clinicaltrials.gov.**
John Zurasky, M.D.
BARD (C.R. Bard, Bard Medical)
- Providence St. Vincent Medical Center